Navigation Links
VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
Date:8/19/2007

- U.S. Patent Office Presented with Documentation Including 15 Prior Art

References Demonstrating Patent Invalidity -

WOBURN, Mass., Aug. 15 /PRNewswire/ -- VisEn Medical, Inc. today filed an inter partes re-examination request with the U.S. Patent and Trademark Office (USPTO) to invalidate and revoke claims of the Caliper Life Sciences (Nasdaq: CALP) patent US 7,255,851, which issued yesterday. VisEn initiated this action as part of its mission to enable leading research, pharmaceutical, and clinical institutions worldwide to develop, apply, and expand their use of fluorescence in vivo imaging from pre-clinical research through clinical medicine. As a basis for the filing, VisEn presented 15 published prior art references demonstrating the invalidity of the '851 patent, the majority of which had not been previously considered by the USPTO.

The claims in the Caliper (formerly Xenogen) '851 patent relate to basic methods in optical in vivo imaging. However, prior to the July 1994 priority date of the '851 patent, numerous investigators worldwide had researched, developed, and published on basic methods, as well as on significant advances, in the field of optical in vivo imaging, including the use of: (i) light- generating systems used to propagate light through tissues; (ii) light- emitting molecules, conjugates, and entities used in vivo to enhance image contrast and specificity; and (iii) instrumentation and methods for the detection and images construction of the emitted light. Collectively, this early research set the foundation for the further development of the optical in vivo imaging technologies now utilized in the fields of research, drug development and healthcare. This early publ
'/>"/>

SOURCE VisEn Medical, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... 2011 Vaccinex, Inc. announced today that it has ... 1 clinical trial to assess the safety, tolerability, pharmacokinetics ... patients with advanced solid tumors. (Logo: ... antibody that blocks the activity of semaphorin 4D (SEMA4D). ...
... 4, 2011 Zeus, Inc., a global leader in ... expanded its capabilities and is now able to process ... Class 7 manufacturing environment. This expansion allows for the ... environment, resulting in compliance with stricter regulatory standards. ...
... announces that a new market research report is ... Opportunities in Biosimilar and Biobetter Drugs Markets ... Executive SummaryThe biosimilar and biobetter drugs market has ... following a series of changes in regulatory framework ...
Cached Biology Technology:Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Calif. The largest genome-wide association study ever ... cat allergies, has identified 16 new genetic associations ... collaboration between 23andMe, the leading personal genetics company, ... Children (ALSPAC), examined data for more than 53,000 ...
... the Denver Police Crime Lab and the University of Colorado, have ... leukocyte (white blood cell) and a cancer cell fuse to form ... ONE , may answer the question of how cancer cells travel ... tissues of the body the deadly process of metastasis. ...
... and medical students each received a one-year, $40,000 ... psoriatic arthritis. The National Psoriasis Foundation Amgen Medical ... scientists studying and treating psoriatic diseases by encouraging ... and psoriatic arthritis as physician researchers. The ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 2National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 3
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. ... and CHAPSO. Has reduced electrostatic interactions that ... on DEAE-cellulose. Aggregation number: 8-16. Purity: ... 2 O. Aggregation number 8 - 16, ...
... White crystalline solid. HYGROSCOPIC. Water-soluble zwitterionic detergent ... 252005) but differing in the length of ... extraction of mycoplasma membrane antigens under mild ... TLC. Soluble in H 2 O. ...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: